cizolirtine has been researched along with aprepitant in 1 studies
| Studies (cizolirtine) | Trials (cizolirtine) | Recent Studies (post-2010) (cizolirtine) | Studies (aprepitant) | Trials (aprepitant) | Recent Studies (post-2010) (aprepitant) |
|---|---|---|---|---|---|
| 22 | 5 | 2 | 769 | 229 | 521 |
| Protein | Taxonomy | cizolirtine (IC50) | aprepitant (IC50) |
|---|---|---|---|
| Cytochrome P450 3A4 | Homo sapiens (human) | 0.046 | |
| Substance-P receptor | Homo sapiens (human) | 0.0002 | |
| Substance-P receptor | Meriones unguiculatus (Mongolian gerbil) | 0.0001 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lazzeri, M | 1 |
1 other study(ies) available for cizolirtine and aprepitant
| Article | Year |
|---|---|
Editorial comment on: Cizolirtine citrate, an effective treatment for symptomatic patients with urinary incontinence secondary to overactive bladder: a pilot dose-finding study.
Topics: Acetanilides; Adrenergic beta-3 Receptor Agonists; Animals; Aprepitant; Female; Humans; Morpholines; Pyrazoles; Receptors, Neurokinin-1; Thiazoles; Urinary Bladder; Urinary Bladder, Overactive; Urinary Incontinence; Urodynamics | 2009 |